We studied the systemic and renal hemodynamic effects of leukotriene C 4 (2 g g per min for 5 minutes, iv) in the rat. During the period of its infusion, leukotriene C 4 produced a significant elevation of mean arterial pressure and reductions in cardiac output and renal blood flow, as measured by electromagnetic flow probes. These effects were abolished by FPL55712, a putative antagonist of sulfidopeptide leukotrienes, but not by saralasin or indomethacin. Leukotriene C 4 also resulted in an average loss of 20% in plasma volume which, during the postinfusion period, perpetuated the low cardiac output state and thus provoked the release of angiotensin II. This vasoactive peptide sustained the elevation in systemic vascular resistance and the reduction in renal blood flow over a 70-minute postinfusion observation period. Consequently, glomerular filtration rate fell by approximately 50%. These angiotensin II-mediated effects were abolished by saralasin. Indomethacin prevented the leukotriene C 4 -induced loss of plasma volume and, thus, allowed for the significant recovery of cardiac output and renal blood flow during the postinfusion period, thereby preserving glomerular filtration rate. We conclude that leukotriene C 4 exerts direct systemic and renal vasoconstrictor, as well as cardiodepressant effects, during the period of its infusion. By virtue of its vasopermeability enhancing effect, leukotriene C 4 also results in an immediate loss of plasma volume, an effect which requires the presence of secondarily generated cyclooxygenase products and which perpetuates the hemodynamic abnormalities observed beyond the period of leukotriene C 4 infusion. (Circ Res 54: 492-499, 1984) infusion of LTC, in group VI animals. *P < 0.05 vs. C for mean ± SEM.
LEUKOTRIENES (LT) are products of arachidonic acid metabolism which are formed via the 5-lipoxygenase pathway . The sulfidopeptide leukotrienes, 5S-hydroxy-6K-Sglutathionyl -7,9 -trans -11,14 -ci's-eicosatetraenoic acid (LTC 4 ), 5S-hydroxy-6K-S-cysteinylglycyl-7,9fra«s-ll,14-cfs-eicosatetraenoic acid (LTD 4 ), and 5Shydroxy -6R -S -cysteinyl -7,9 -trans-11,14 -ciseicosatetraenoic acid (LTE 4 ), together constitute the activity previously known as slow reacting substance of anaphylaxis (SRS-A) Lewis et al., 1980a Lewis et al., , 1980b Morris et al., 1980) . These compounds elicit arteriolar constriction and augmentation of vascular permeability to macromolecules in postcapillary venules (Drazen et al., 1980; Lewis et al., 1980b; Dahlen et al., 1981) , cardiodepression due to coronary arteriolar constriction (Burke et al., 1982; Letts and Piper, 1982; Michelassi et al., 1982; Smedgard et al., 1982; Pfeffer et al., 1983) and pulmonary bronchoconstriction (Dahlen et al., 1980; Hanna et al., 1981; Smedgard et al., 1982; Weiss et al., 1982; Weiss et al., 1983) . A separate product derived from the 5-lipoxygenase pathway, 5S, 12R-dihydroxy-6,14-c/s-8,10-f rans-eicosatetraenoic acid (LTB 4 ) is a granulocyte chemotactic factor which increases leukocyte adhesion to endo-thelial surfaces and causes leukocyte-leukocyte aggregation (Smith et al., 1980; Goetzl and Pickett, 1981; Palmblad et al., 1981; Showell et al., 1982) . The biosynthesis of LTC 4 and LTB 4 is carried out by activated neutrophils, eosinophils, and monocytemacrophages in a number of mammalian species, including the rat (Lewis et al., 1980a; Bach et al., 1980) and the human Fels et al., 1982; Weller et al., 1983) , and these products could play a role in mediating the microvascular, and possibly systemic, pathophysiological consequences of tissue injury .
In the present studies, the direct and indirect effects of intravenously administered LTC 4 on mean arterial pressure (AP), cardiac output (CO), renal blood flow (RBF), systemic and renal vascular resistances (SVR and RVR), plasma volume (PV), and glomerular filtration rate (GFR) are described in the rat. By pretreating rats with the putative leukotriene receptor blocker, FPL55712 (Augstein et al., 1973; Fleisch et al., 1982) , the cyclooxygenase inhibitor indomethacin (Vane, 1971) , and the angiotensin receptor antagonist, saralasin (Streeten et al., 1976) , the direct effects of LTC 4 could be separated from those of secondarily generated cyclooxygenase products and of angiotensin II. Methods LTC 4 was prepared by total organic synthesis, as previously described , and was stored under argon at -80°C in 20 mM sodium phosphate buffer, pH 6.8: ethanol, 4:1 (vol/vol). For each experiment, the LTC 4 stock solution and the vehicle, lacking LTC 4 , were diluted to final concentration in 0.9% sodium chloride solution. Indomethacin and saralasin were purchased from Sigma Chemical Co. and FPL55712 was a gift from the Fisons Corp., Loughborough, U.K.
Experiments were performed on adult male Munich-Wistar rats (200-330 g) maintained on a standard rat pellet diet and allowed free access to water. Each rat was anesthetized with Inactin (100 mg/kg, ip) and placed on a heated surgical table so that body temperature was maintained at 36.5 to 37.5°C throughout the course of the experiment. Polyethylene catheters (PE 50) were placed in the left femoral artery and vein. The arterial catheter was used for blood sampling and measurement of AP with an electronic transducer (model P23Db, Statham Instruments Division, Gould Inc.) connected to a direct writing recorder (model 7754A, Hewlett-Packard Co.). The venous catheter was used for infusion of homologous rat plasma as required to maintain euvolemia (Ichikawa et al., 1978) . After a tracheostomy, PE 50 catheters were introduced into both jugular veins for the administration of a 7% inulin solution in 0.9% NaCl at the rate of 1.2 ml/hr, and for infusion of LTC 4 or vehicle. The left kidney was exposed via a subcostal incision and the left ureter was catheterized with PE 10 tubing. An electromagnetic flow probe (i.d. = 1.5 mm) was placed around the left renal artery and connected to a flowmeter (Carolina Medical Electronics, model 501), the output of which was displayed on a second channel of the Hewlett-Packard recorder. In rat groups designated IV and V, the tracheal cannula was connected to a small-animal ventilator, an anterior thoracotomy was performed, and an electromagnetic flow probe (i.d. = 2.0 mm, Statham) was placed on the ascending aorta for continuous monitoring of CO on a third channel of the Hewlett-Packard recorder.
After a 45-to 60-minute period during which AP, RBF, urine flow, and CO were constant, two 15-minute clearance measurements were performed, and control values for AP, RBF, and CO were recorded. Vehicle or LTC 4 solution was then administered at a rate of 0.1 ml/min (2 fig LTC 4 /kg per min) for 5 minutes. Hemodynamic indices were monitored continuously throughout the infusion of either vehicle or LTC 4 and observed for an additional 70-minute postinfusion period in groups I, II, III, and VII and for 15 minutes in groups IV and V. Clearance measurements were repeated during the postinfusion period.
The experimental groups were designated as follows: Group IA: infusion of vehicle followed by a second infusion of vehicle (n = 6). Group IB: infusion of vehicle followed by infusion of LTC« (n = 12).
Group II: infusion of vehicle followed by LTC 4 , each in the presence of saralasin, 5 MgAg per min, iv (n = 6).
Group III: infusion of vehicle followed by LTC 4 , each in the presence of indomethacin, 2 mg/kg, over 10 minutes, followed by 2 mg/kg per hr, iv (n = 7).
Group IV: infusion of vehicle followed by LTC 4 in animals with thoracotomy and monitoring of CO (n = 7). In six animals, rat plasma (1.5-2 ml over 5 minutes was infused 15 minutes after LTC 4 infusion in order to restore hematocrit to pre-LTC 4 values (see below).
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Group V: infusion of vehicle followed by LTC 4 in the presence of indomethacin in animals with thoracotomy and monitoring of CO (n = 4).
Group VI: red blood cell (RBC) volume determined using "Cr-labeled cells (Sterling and Gray, 1950) , both before and after vehicle administration and again after LTC 4 infusion (n = 8).
Group VII: FPL55712, 500 Mg/kg per min, infused beginning 1 minute before and terminating 1 minute after the LTC<jnfusion (n = 5).
Since AP, RBF, and CO were constant for 45-60 minutes prior to LTC 4 or vehicle infusion, values for those parameters obtained immediately prior to LTC 4 or vehicle administration were considered as preinfusion controls. These measurements were compared to those observed at the end of the 5-minutes LTC 4 infusion, as well as to those which were obtained 15 minutes after the end of this infusion (i.e., minute 20, on Figs. 1, 2, and 4). This last point was chosen to represent postinfusion values for the purposes of statistical analysis since, at 20-75 minutes postinfusion, AP, RBF, and CO were constant. End infusion and postinfusion values within groups were compared with preinfusion controls, using a one-way analysis of variance with a Bonferroni correction for multiple preplanned comparisons. GFR, Hct, and RBC volumes were measured twice within each group: before LTC 4 infusion, and also during the postinfusion period (min 5-20). These two values were compared by paired Student's f-test. In all comparisons, a P value of < 0.05 was required for statistical significance. Results are presented as means ± SEM.
Results
AP remained at preinfusion levels (106 ± 4 mm Hg) throughout the vehicle infusion period (maximally 108 ± 3 mm Hg, mean ± SEM, group IA). Administration of LTC 4 resulted in an immediate elevation in AP from a baseline of 114 ± 3 to 125 ± 3 mm Hg, (P < 0.001, group IB) ( Fig. IA) and a return to control levels within 1-2 minutes of stopping the infusion. The presence of_saralasin did not prevent an LTQ-induced rise in AP from 122 ± 5 to 133 ± 5 mm Hg, (P < 0.005, group II), nor did indomethacin (107 ± 4 to 119 ± 4 mm Hg, P < 0.001, group III); neither treatment prolonged the LTC4-induced elevation in AP beyond the infusion period. In contrast, the addition of FPL55712 to the infusion prevented any significant increase in AP (122 ± 7 mm Hg) due to LTC 4 (126 ± 6 mm Hg, group VII) ( Fig. IB) .
RBF (6.9 ± 0.6 ml/min preinfusion) was not significantly affected by vehicle infusion (7.3 ± 0.6 ml/ min immediately postinfusion, group IA). LTC 4 administration resulted in an immediate reduction in RBF from 6.5 ± 0.3 which progressed to 5.0 ± 0.3 ml/min (P < 0.001, group IB), at 5 minute and to a nadir of 4.3 ± 0.4 ml/min in the immediate postinfusion period, and was persistently depressed over the entire 65-minute period of subsequent measurements ( Fig. 2A ). Although the fall in RBF which occurred during the infusion of LTC 4 in the presence of saralasin (6.4 ± 0.3 to 5.4 ± 0.3 ml/min, P < 0.025, group II) or indomethacin (6.6 ± 0.3 to 5.7 ± 0.3 ml/min, P < 0.01, group III) was significant, RBF returned to normal 5 minutes (indomethacin) and 15 minutes (saralasin) after stopping LTC4 infusion ( Fig. 2A ). LTCj-mediated changes in RBF were completely prevented by FPL55712 (6.7 ± 0.2 to 6.7 ± 0.2 ml/min, group VII) ( Fig. 2B) . GFR (0.90 ± 0.10 ml/min) was unaffected by administration of vehicle (0.91 ± 0.10 ml/min, group IA). In contrast, LTC 4 infusion resulted in a reduction in GFR from 0.90 ± 0.10 to 0.46 ± 0.12 ml/min (P < 0.005, group IB) (Fig. 3) . The LTC 4 -induced fall in GFR was prevented by saralasin infusion (1.01 ± 0.03 pre-LTC 4 vs. 0.94 ± 0.10 ml/min post-LTC 4 infusion, group II), pretreatment with indomethacin (0.98 ± 0.08 preinfusion vs. 0.98 ± 0.10 ml/min postinfusion, group III) and the presence of FPL55712 (0.95 ± 0.01 preinfusion vs. 1.10 ± 0.12 ml/min postinfusion, group VII) (Fig. 3) .
A significant reduction in CO from 35.4 ± 1.8 to 26.5 ± 2 ml/min occurred 1-2 minute after the initiation of the LTC 4 infusion. By the end of the LTC4 infusion, CO had fallen to a minimum of 23.5 ± 0.8 ml/min (P < 0.01, group VI) and remained depressed for the remaining 15 minutes of observation (Fig. 4A ). The reduction in CO was accompanied by a rise in SVR from 2.7 ± 0.2 to 4.5 ± 0.2 mm Hg/ml per min (P < 0.05) at 5 minutes and to 3.7 ± 0.3 mm Hg/ml per min (P < 0.025) at 20 minute (Fig. 4B ). Pretreatment with indomethacin (group V) prevented the fall in CO during LTC 4 infusion (34.6 ± 4.4 preinfusion to 28.8 ± 5.0 ml/ min immediately postinfusion), as well as during the postinfusion observation period_(32.2 ± 4.0 ml/min) (Fig. 4A ). The responses of AP, RBF, and GFR to LTC 4 infusion in animals subjected to thoracotomy, without or with indomethacin pretreatment (groups IV and V, respectively), were similar to those of animals treated under the same protocol, but without thoracotomy (groups IB and III, respectively). Vehicle administration had no effect on hematocrit (Hct) (47.6 ± 0.6 preinfusion vs. 47.3 ± 0.7 vol% postinfusion, group IA), whereas infusion of LTC 4 resulted in an immediate and sustained increase in Hct (47.4 ± 0.7 vs. 51.9 ± 0.9 vol%, P < 0.001, group IB) (Fig. 5) was also seen in the saralasin-treated animals (47.3 ± 0.4 vs. 51.8 ± 0.4 vol%, P < 0.001, group II) and in animals subjected to thoracotomy (45.7 ± 0.6 vs. 49.6 ± 1.0 vol%, P < 0.001, group IV). Animals pretreated with indomethacin, and either without thoracotomy (48.0 ± 0.6 to 48.8 ± 0.7 vol%, group III) or with thoracotomy (43.5 ± 1.2 to 43.3 ± 1.5 vol%, group V), or animals receiving FPL55712 (47.5 ± 0.7 vs. 47.4 ± 0.7 vol%, group VII) did not have a rise in Hct (Fig. 5 ). Measurements of RBC volume and Hct before and after LTC 4 infusion in group VI demonstrated that the former parameter remained constant (7.9 ±0.1 preinfusion to 7.6 ± 0.2 ml postinfusion), while Hct increased from 49.4 ± 0.6 to 53.4 ± 1.0 vol% (P < 0.005). Thus, calculated PV was significantly reduced, on the average from 8.2 ± 0.3 to 6.5 ± 0.4 ml (P < 0.005) (Fig. 6) . In six of the seven animals in group IV, PV losses were replaced 15 minutes after cessation of LTC 4 infusion by restoring Hct in each animal to its pre-LTC 4 level. This replacement of PV effected an almost complete recovery of CO, SVR, RBF, and RVR (Fig. 7) .
Discussion
In the present study, the intravenous administration of LTC 4 to Munich-Wistar rats led to an increase in SVR which, despite a progressive fall in CO (Fig.   -4 - 4 A), resulted in a net increase in AP of ~10 mm Hg (Fig. 1A) . The likelihood that this effect is due to a direct action of LTC4 is suggested by its occurrence in the presence of saralasin (group II) or indomethacin (group III), the coincidence of its rime course with that of LTC* administration, and its abrogation by the LTC 4 end-organ antagonist,_FPL55712 (Fig.  1, A and B) . The normalization of AP in the post-LTC 4 infusion period is attributable to the balance between decreased CO and increased SVR, as has been reported previously (Pfeffer et al., 1983) . The fall in CO during and after LTC 4 infusion was not significant in the presence of indomethacin (Fig. 4) , and was thereby probably evoked by a secondarily generated cyclooxygenase product (Fig. 4) .
Despite an increase in renal perfusion pressure during LTC4 administration, in parallel with the increase in AP, there was a significant reduction in RBF due to a marked increase in RVR. Since the fall in RBF and the calculated rise in RVR is blunted, but not abolished, by either indomethacin or saralasin (Fig. 2) , it is presumed to result from the combined effects of LTC 4 and secondarily released endogenous vasoconstrictors. That the major proportion of the rise in RVR persists in the presence of saralasin and indomethacin ( Fig. 2A) , but is abrogated by FPL55712 (Fig. 2B) suggests that direct LTC 4 -mediated vasoconstriction is the principal underlying mechanism. This finding substantiates recent observations by Rosenthal and Pace-Asciak (1983) who demonstrated potent vasoconstriction of the isolated, perfused rat kidney by LTC 4 and LTD 4 which was inhibitable by FPL55712 but not by indomethacin or OKY-1581, a presumed inhibitor of thromboxane synthesis. In the post-LTC 4 infusion period, no recovery in RBF was noted (group IB), whereas complete recovery occurred in animals infused with LTC 4 and saralasin simultaneously (group II) or pretreated with indomethacin before LTC 4 infusion (group III) ( Fig. 2A) . The recovery of renal perfusion in these animals indicates that the direct action of LTC 4 on RVR is limited to the period of its infusion. Further, the capacity of saralasin to abolish this effect completely suggests that endogenously released angiotensin II mediates the persistent increase in RVR in the postinfusion period. The capacity of indomethacin to produce a recovery of RBF implicates the action of one or more cyclooxygenase products in the same cascade that leads to angiotensin II release and renal vasoconstriction. Finally, since the leukotriene antagonist FPL55712 abolished the fall in RBF which occurred during the infusion of LTC 4 and, also, that occurring during the postinfusion period (Fig. 2B) , it is likely that a primary effect of LTC 4 is required for the persistent secondary events to ensue.
In rats treated with LTC 4 (group IB), GFR fell by nearly 50%, as shown by comparison of inulin clearances in the pre-and postinfusion periods (Fig. 3) . That no change in GFR was noted in rats that LTCt (2 fig/kg per min) for 5 minutes, IV) in the rat. Those responses resulting from arteriolar vasoconstriction are seen dunng the period of infusion and are abrogated only by FPL5571Z whereas those resulting from increased vascular permeability are responsible for sustaining a low CO in the postmfusion period and are blocked by FPL5571Z as well as by indomethacin. Secondarily released angiotensin 11 (All) sustains an elevated SVR and RVR during the postinfusion period, and its effects are blocked by saralasm.
received LTC 4 in the presence of saralasin (group II), indomethacin (group III), or FPL55712 (group VII) ( Fig. 3) implies that the presence or absence of a persistent fall in renal perfusion ( Fig. 2A) was critical. Further, since the fall in GFR in group IB was proportionately greater than the fall in renal plasma flow (i.e., filtration fraction fell on the average from 0.27 to 0.21), another mechanism, in addition to the fall in RBF, must pertain. The efficacy of saralasin in abolishing the LTC 4 -mediated fall in RBF and GFR, coupled with a previous demonstration of the capacity of angiotensin II to lower the glomerular capillary ulrrafiltration coefficient (K f ) (Blantz et al., 1976) , suggests that an angiotensin IImediated fall in K f may be the additional factor. Confirmation of this possibility awaits precise quantification of the renal microcirculatory changes following LTC 4 infusion. FPL55712, by preventing all of the LTC 4 -mediated changes in renal and systemic hemodynamics, also prevented the fall in GFR.
Acute hemoconcentration accompanied the administration of LTC 4 in all animals except those treated with indomethacin or FPL55712 (Fig. 5) and was due largely to a fall in circulating PV (Fig. 6) . The average 20% loss of PV is consistent with the known potency of LTC 4 for increasing the permeability of postcapillary venules to fluid and macromolecules (Drazen et al., 1980; Lewis et al., 1980b; Dahlen et al., 1981) and significantly contributes to the hemodynamic abnormalities observed in the postinfusion period. That indomethacin prevents LTC 4 -infused PV losses, as evidenced by a stable hematocrit in groups III and V (Fig. 5) , is not only consistent with the capacity of LTC 4 to stimulate cyclooxygenase product generation by some cells and tissues (Feuerstein et al., 1981; Folco et al., 1981; Cramer et al., 1983) , but also extends previous reports regarding potentiation of leukotriene-mediated local vasopermeability by certain cyclooxygenase products (Williams and Piper, 1980; Wedmore and Williams 1981; Soter et al., 1983) . By preventing PV losses, indomethacin prevents a significant fall in CO in the post-LTC 4 infusion period (Fig. 4A) , and, so, presumably prevents the release of endogenous angiotensin II. Thus, systemic, coronary, and renal vascular resistances promptly return to their respective control levels as evidenced by the normalization of SVR (Fig. 4B ) and RBF ( Fig. 2A ) and preservation of GFR (Fig. 3) . This is further supported by observations on saralasin-treated rats (group II) wherein PV losses occur and CO is presumably depressed, but RVR, RBF, and GFR remain stable during the postinfusion period. That the LTC 4 -evoked losses of PV are of primary importance in mediating the postinfusion hemodynamic abnormalities is substantiated by their reversal with PV replacement (Fig. 7) .
In summary, the intravenous administration of LTC 4 in the rat produces striking intrainfusion and postinfusion pathophysiological responses. (Fig. 8) . During intravenous infusion, the direct vasoconstrictor actions of LTC 4 on coronary, renal, and systemic arteriolar beds, respectively, decrease myocardial performance and CO, decrease RBF, and increase AP. Postinfusion responses result from LTC 4 -mediated increases in vascular permeability which are secondarily dependent upon cyclooxygenase product generation and are blocked by in-domethacin. When unopposed, the fall in PV perpetuates the depression in CO and in RBF. Endogenously released angiotensin II sustains an increase in RVR, thereby exacerbating the depression in RBF. GFR declines-in part, due to the fall in RBF, and, in addition, due to a likely, but as yet unproven, reduction in K f , presumably mediated by angiotensin II (Blantz et al., 1976) .
The physiological alterations that occur during LTC 4 infusion appear to be a direct consequence of the LTC 4 and are presumably mediated by a specific ligand-receptor interaction as has been recently described for a cultured smooth muscle cell line (Krilis et al., 1983) . If this is the case, the antagonism of these direct effects by FPL55712 could not have been anticipated from previous studies of either receptor-ligand binding (Krilis et al., 1983) or physiological responses, as assayed in guinea pig pulmonary parenchymal strips in vitro (Drazen et al., 1980) . In both experimental settings, FPL55712 was not a potent antagonist for LTC 4 -tissue interactions. Indeed, the potent antagonistic effects of FPL55712 on LTD 4 -mediated pulmonary parenchymal strip contraction and the lack of LTD« competition for the LTC 4 receptor on the smooth muscle cell line and a subcellular fraction from rat lung homogenate have been used as arguments for the existence of separate LTC 4 and LTD 4 receptors (Drazen et al., 1980; Pong et al., 1983; Krilis et al., in 1983) . Therefore, the present observations raise the possibility that such vascular LTC 4 receptors as might exist have a different order of ligand specificity than those previously appreciated in nonvascular smooth muscle or that the conversion of LTC 4 to LTD 4 is responsible for evoking the observed physiological responses.
